Cardiac Surgery
#AHA21 – M-A: Among patients with left main coronary disease, there was no statistically significant difference in 5-year all-cause death between percutaneous coronary intervention with drug-eluting stents vs. coronary artery bypass grafting.
16 Nov, 2021 | 08:31h | UTCPercutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis – The Lancet (free registration required)
Commentary: No Mortality Difference Between PCI and CABG for Left Main PCI: Meta-analysis – TCTMD
Review and algorithm: Dysphagia aortica.
16 Nov, 2021 | 08:19h | UTCDysphagia aortica – European Surgery
#AHA21 – RCT: Concomitant tricuspid repair in patients undergoing surgery for degenerative mitral regurgitation reduced tricuspid regurgitation progression but increased the need for permanent pacemaker implantation.
14 Nov, 2021 | 20:00h | UTCConcomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years – TCTMD
CTCR-MVS: Concomitant Tricuspid Repair in Patients With MR – American College of Cardiology
#AHA21 – RCT: In asymptomatic patients with severe aortic stenosis, early surgery improved outcomes compared to conservative treatment.
14 Nov, 2021 | 20:01h | UTCAortic Valve ReplAcemenT versus Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis: The AVATAR Trial – Circulation (free for a limited period)
News release: Surgery to replace heart valve beneficial even with no symptoms of severe aortic stenosis – American Heart Association
Commentaries:
AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients – TCTMD
Related study: #AHA19 – Randomized Trial: Early Surgery Improves Outcomes in Asymptomatic Patients with Very Severe Aortic Stenosis
Commentary on Twitter
#OriginalResearch SimPub#AHA21: The #AVATAR RCT of 157 patients with asymptomatic severe #AS and normal LVEF found that early #SAVR associated w/reduced composite outcome of death, MI, stroke or HF hospitalization compared to mgmt. https://t.co/SdMiWHOPnp #AHAJournals pic.twitter.com/jCcWVZfzse
— Circulation (@CircAHA) November 13, 2021
#AHA21 – RCT: Among patients undergoing cardiac surgery, routine posterior left pericardiotomy can prevent postoperative atrial fibrillation.
14 Nov, 2021 | 19:53h | UTCPosterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial – The Lancet (free registration required)
Commentaries:
A short cut to prevent postoperative atrial fibrillation – The Lancet (free registration required)
#AHA21 – [Not published Yet] A small, randomized study showed stopping ticagrelor only 2-3 days before bypass surgery may be safe.
14 Nov, 2021 | 19:56h | UTCCommentary: RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor – TCTMD
Lessons from a Superb Clinical Trial – commentary on a recent randomized trial testing left atrial appendage occlusion during cardiac surgery to prevent stroke.
9 Nov, 2021 | 01:08h | UTCLessons from a Superb Clinical Trial – by Dr. John Mandrola
RCT: In patients with three-vessel coronary artery disease, an FFR–guided PCI strategy was NOT noninferior to coronary bypass surgery – The 1-year incidence of the composite primary end point (death, myocardial infarction, or stroke) was 7.3% in the FFR-guided PCI group and 5.2% in the CABG group.
5 Nov, 2021 | 09:49h | UTCCommentaries:
FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD – TCTMD
FAME 3: FFR-Guided PCI vs. CABG in Patients With Three-Vessel CAD – American College of Cardiology
Commentary on Twitter
In this trial, patients with three-vessel coronary artery disease, PCI guided by assessment of fractional flow reserve was not noninferior to CABG with respect to the composite end point of death, myocardial infarction, stroke, or repeat revascularization. https://t.co/uYZGZWub0T pic.twitter.com/zsghs2SlsA
— NEJM (@NEJM) November 4, 2021
Guidelines for anesthesiologists on patient blood management in cardiac surgery.
17 Oct, 2021 | 21:22h | UTC
Commentary on Twitter
Please check out editorial on patient #blood management in #cardiacsurgery, a collaboration between Society of Thoracic Surgeons, Society of Cardiovascular Anestheisologists and SABM, AmSECT. https://t.co/HHA8SjxNot pic.twitter.com/DAj2TrGYC3
— Jiapeng Huang (@jiapenghuang) September 24, 2021
Varied extent of mitral annular disjunction among cases with different phenotypes of mitral valve prolapse.
7 Oct, 2021 | 10:12h | UTC
Commentary on Twitter
Varied Extent of #MAD Among Cases With Different Phenotypes of #Mitral Valve #Prolapse ➡️ 3D #YesCCT ➡️ https://t.co/7q4GqIAZQd @JACCJournals @UCLA @argulian @purviparwani @MinnowWalsh @BakhshiHooman @MrinShettyMD @mividovich #JACCCaseReports @gina_lundberg @chiarabd @EstefaniaOS pic.twitter.com/6gVnaBg3cb
— Julia Grapsa (@JGrapsa) August 18, 2021
Review: Coronary artery anomalies.
28 Sep, 2021 | 09:02h | UTCCoronary Artery Anomalies – Circulation (free for a limited period)
Commentary on Twitter
#InDepth Review highlighting current diagnostic and therapeutic approaches to Coronary Artery Anomalies https://t.co/TB5HWvgHiE #AHAJournals pic.twitter.com/OaCGUNSPfW
— Circulation (@CircAHA) September 23, 2021
#ESCCongress – 2021 ESC/EACTS Guidelines for the management of valvular heart disease – in the new guidelines, more patients are eligible for surgical and transcatheter interventions, based not only on symptoms but also on imaging criteria.
29 Aug, 2021 | 18:23h | UTCNews release: European valvular heart disease Guidelines published today – European Society of Cardiology
Summary: 2021 ESC/EACTS Valvular Heart Disease Guidelines: Key Points – American College of Cardiology
Commentary: Revamped Valve Disease Guideline: Europe Sees Nearly Eye to Eye With U.S. – MedPage Today (free registration required)
“In line with recent U.S. recommendations, the newest European guidelines favor a wider pool of patients eligible for surgical and transcatheter interventions for valvular heart disease.” (from MedPage Today)
Commentaries on Twitter
#ESCCongress new VHD guidelines out ➡️https://t.co/fFkuivAM9E
➡️SAVR in low risk pts <75yrs old
➡️ TAVR in pts >75
➡️ Role of heart team emphasised
➡️ NEW! intervention to be considered with asymptomatic AS with lv <55% IIa@HanCardiomd @Hragy @aayshacader @DrMarthaGulati #TAVR pic.twitter.com/JV1zocQJaK— Mamas Mamas (@mmamas1973) August 28, 2021
?Guidelines for the management of valvular heart disease #ESCCongress @escardio @secardiologia @EACTS
? https://t.co/3FCS8YYKIr @mmamas1973 @shci_sec pic.twitter.com/wxuf3AjVaE
— Alfonso Valle (@ValleAlfonso) August 28, 2021
Optimal antithrombotic therapy for valve prostheses from the 2021 #ESC Guidelines for the management of VHD #ESCCongress @escardio https://t.co/AmQJkZBMoo pic.twitter.com/WK2wQSSlhL
— Roxana Mehran (@Drroxmehran) August 28, 2021
(thread – click for more)
Have there been changes in when to intervene with the new 2021 ESC/EACTS guidelines for the management of valvular heart disease?
Yes, and in general the bar for intervention is now lower
Thread follows…#ESCCongress
1/n pic.twitter.com/iLN9cLCtLj
— Sarah Hudson (@sarahhudsonuk) August 28, 2021
Donor drug use is not associated with worse recipient survival in heart transplantation – “Increasing use of such donors may help alleviate the chronic donor shortage.”
30 Jul, 2021 | 11:39h | UTCIntoxicated Donors and Heart Transplant Outcomes: Long-Term Safety – Circulation: Heart Failure
Commentary: Donor Drug Use Not Tied to Survival for Heart Transplant Recipients – HealthDay
Related study: National Trends in Heart Donor Usage Rates: Are We Efficiently Transplanting More Hearts? – Circulation: Heart Failure
ESC Consensus Document: Antithrombotic therapies in aortic and peripheral arterial diseases in 2021.
28 Jul, 2021 | 09:56h | UTCKey Points to remember: ESC Consensus on Antithrombotic Therapies in Aortic and Peripheral Artery Diseases – American College of Cardiology
Commentary on Twitter
The new consensus document from the ESC working group on aorta and peripheral vascular diseases on best antithrombotic strategies!#aorta #antithrombotic #therapy #EHJ #cardiotwitter@escardio @ESC_Journals https://t.co/ga17wxKDGi pic.twitter.com/CSSgE5TFdX
— EHJ Editor-in-Chief (@ehj_ed) July 23, 2021
Expert consensus: Multimodality imaging of myocardial viability.
28 Jul, 2021 | 09:46h | UTC
Commentary on Twitter
Proud to be actor of the EACVI expert consensus document about MMI of myocardial viability.
Congratulations to @bernhard_gerber for the magnificent job as work leader!https://t.co/wewpY5BVGQ@carpenter_jp @DonalErwan @sven_plein @denisamuraru @maceiraCMR @MarcDweck @unisiena pic.twitter.com/kdxZL3wQxW— Matteo Cameli, MD, PhD (@Matte_Cameli) June 8, 2021
International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes.
26 Jul, 2021 | 02:27h | UTC
Commentary on Twitter
Consensus Statement on Nomenclature and Classification of the Congenital Bicuspid Aortic Valve https://t.co/Uux9d40kkj pic.twitter.com/LA8dfuWv90
— CM Otto (@ottoecho) July 22, 2021
Position Statement on Endomyocardial Biopsy.
23 Jul, 2021 | 10:33h | UTC
Commentary on Twitter
?A must read – out now in JCF: Position Statement on Endomyocardial Biopsy ? – @HFSA @escardio @ESCardioNews #CardioTwitter #FunctionNotFailure #HeartSuccess @rcstarling @MRMehraMD @BiykemB @Filippatos @robmentz @dranulala https://t.co/33FPZDBviN pic.twitter.com/VJEzGLIRIg
— Journal of Cardiac Failure (@JCardFail) July 21, 2021
WHO issues new recommendations on human genome editing for the advancement of public health.
13 Jul, 2021 | 09:42h | UTCSee reports:
Human genome editing: recommendations
Human genome editing: a framework for governance
Commentaries: New Global Recommendations for Human Genome Editing may Improve Use to Cure and Treat Diseases – Health Policy Watch AND WHO should lead on genome-editing policy, advisers say – Nature AND WHO Calls for Global Registry of Human Genome Editing – HealthDay AND Expert reaction to the WHO’s newly published recommendations and governance framework for human genome editing – Science Media Centre
Commentary on Twitter (thread – click for more)
Two ? reports provide the first global recommendations to help establish human genome ? editing as a tool for public health, with an emphasis on safety, effectiveness and ethics.
? https://t.co/w32QhMXSXi pic.twitter.com/Bto9SF6NzW
— World Health Organization (WHO) (@WHO) July 12, 2021
AHA Scientific Statement: Mechanical Complications of Acute Myocardial Infarction.
16 Jun, 2021 | 08:21h | UTC
RCT: Low tidal volume ventilation is not superior to no ventilation during cardiopulmonary bypass in heart surgery.
8 Jun, 2021 | 09:16h | UTCLow Tidal Volume Mechanical Ventilation Against No Ventilation During Cardiopulmonary Bypass in Heart Surgery (MECANO): A Randomized Controlled Trial – CHEST (link to abstract – $ for full-text)
#ACC21 – Practice Changing RCT: In patients with atrial fibrillation (75% maintained on anticoagulation), left atrial appendage occlusion during cardiac surgery reduces the incidence of stroke and systemic embolism (4.8 vs. 7.0%) in the following years.
17 May, 2021 | 08:33h | UTCLeft Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Simple surgery prevents strokes in heart patients – McMaster University AND Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III – TCTMD
Video: The Left Atrial Appendage Occlusion Study (LAAOS) III
Commentary on Twitter
A visual abstract of the #ACC21 Left Atrial Appendage Occlusion Study III is now available, evaluating surgical #LAAO compared with no occlusion among patients with #AFib undergoing open heart surgery for another indication. https://t.co/3iIhAEuGwk pic.twitter.com/e9Wq6Bp3Zz
— American College of Cardiology (@ACCinTouch) May 15, 2021
AHA Statement: Prevention of Viridans Group Streptococcal Infective Endocarditis – Antibiotic prophylaxis for invasive dental procedures is suggested only for high-risk patients with the following conditions: 1) cardiac prosthetic valve; 2) previous infective endocarditis; 3) congenital heart disease; or 4) previous heart transplant
30 Apr, 2021 | 08:35h | UTCNews release: Good dental health may help prevent heart infection from mouth bacteria – American Heart Association
Top Things to Know: Prevention of Viridans Group Streptococcal Infective Endocarditis – American Heart Association
Slide set: Prevention of Viridans Group Streptococcal Infective Endocarditis
Commentaries: Commentary for Prevention of Viridans Group Streptococcal Infective Endocarditis – American Heart Association
Commentary on Twitter (thread – click for more)
In 2007, antibiotic prophylaxis to prevent VGS IE was scaled back.
“There was no convincing evidence that VGS IE frequency, morbidity, or mortality has increased since 2007.”
Thanks Drs. @LBaddour1, Daniel DeSimone and Walter Wilsonhttps://t.co/r9It8c3IwA pic.twitter.com/EO3gcKZAzG
— Mayo Clinic Infectious Diseases (@MayoClinicINFD) April 18, 2021
Podcast: Congenital Heart Disease for the General Pediatrician
29 Apr, 2021 | 08:18h | UTC#24: Congenital Heart Disease for the General Pediatrician – The Cribsiders
Opportunities and Challenges for the Next Phase of Enhanced Recovery After Surgery
22 Apr, 2021 | 08:28h | UTCOpportunities and Challenges for the Next Phase of Enhanced Recovery After Surgery: A Review – JAMA Surgery (free for a limited period)
See also: Enhanced Recovery After Surgery (ERAS) Society Guidelines
Cohort Study: Effects of fluoroquinolones on outcomes of patients with aortic dissection or aneurysm
13 Apr, 2021 | 05:05h | UTCRelated: Another study suggests fluoroquinolone use may increase the risk of development of aortic aneurysms (study and commentaries) AND Link between fluoroquinolones, aorta problems may not be as strong as thought AND Study: Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation AND FDA Warns About Increased Risk of Aortic Dissection and Ruptures of Aortic Aneurism with Fluoroquinolones AND Meta-analysis: Fluoroquinolones and the Risk of Aortopathy AND Study: Oral Fluoroquinolone and the Risk of Aortic Dissection AND Research: Fluoroquinolone use and risk of aortic aneurysm and dissection